Harel Insurance Investments & Financial Services Ltd. Sells 81 Shares of Eli Lilly and Company (NYSE:LLY)

Harel Insurance Investments & Financial Services Ltd. decreased its holdings in Eli Lilly and Company (NYSE:LLY) by 20.0% in the fourth quarter, Holdings Channel reports. The firm owned 325 shares of the company’s stock after selling 81 shares during the quarter. Harel Insurance Investments & Financial Services Ltd.’s holdings in Eli Lilly and Company were worth $251,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Exchange Traded Concepts LLC boosted its position in shares of Eli Lilly and Company by 13.9% during the fourth quarter. Exchange Traded Concepts LLC now owns 38,810 shares of the company’s stock valued at $29,961,000 after buying an additional 4,733 shares during the last quarter. CX Institutional boosted its holdings in shares of Eli Lilly and Company by 23.2% during the 4th quarter. CX Institutional now owns 23,623 shares of the company’s stock valued at $18,237,000 after acquiring an additional 4,452 shares during the last quarter. Berbice Capital Management LLC purchased a new stake in shares of Eli Lilly and Company during the 4th quarter valued at about $673,000. Impact Partnership Wealth LLC grew its stake in shares of Eli Lilly and Company by 42.5% in the fourth quarter. Impact Partnership Wealth LLC now owns 1,022 shares of the company’s stock worth $789,000 after acquiring an additional 305 shares during the period. Finally, Sound Income Strategies LLC raised its holdings in shares of Eli Lilly and Company by 0.8% during the fourth quarter. Sound Income Strategies LLC now owns 4,814 shares of the company’s stock valued at $3,716,000 after purchasing an additional 38 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Insider Transactions at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 900 shares of the firm’s stock in a transaction on Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the completion of the sale, the chief accounting officer now directly owns 5,480 shares in the company, valued at $4,402,522.40. This trade represents a 14.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Trading Up 2.4 %

LLY stock opened at $784.78 on Monday. The firm has a fifty day moving average price of $776.69 and a 200 day moving average price of $848.83. Eli Lilly and Company has a fifty-two week low of $624.68 and a fifty-two week high of $972.53. The firm has a market cap of $745.01 billion, a PE ratio of 84.84, a price-to-earnings-growth ratio of 1.59 and a beta of 0.41. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). The business had revenue of $11.44 billion during the quarter, compared to analysts’ expectations of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The business’s quarterly revenue was up 20.4% on a year-over-year basis. During the same period in the previous year, the business earned $0.10 earnings per share. Sell-side analysts anticipate that Eli Lilly and Company will post 12.98 earnings per share for the current fiscal year.

Eli Lilly and Company announced that its board has initiated a stock buyback program on Monday, December 9th that permits the company to repurchase $15.00 billion in shares. This repurchase authorization permits the company to buy up to 2% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s management believes its shares are undervalued.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be paid a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.76%. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.30. The ex-dividend date is Friday, February 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 56.22%.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of research analyst reports. StockNews.com raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, January 22nd. Wolfe Research assumed coverage on Eli Lilly and Company in a report on Friday, November 15th. They issued an “outperform” rating and a $1,000.00 target price on the stock. Bank of America reaffirmed a “buy” rating and issued a $997.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, December 10th. Deutsche Bank Aktiengesellschaft cut their price objective on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating for the company in a research note on Monday, November 4th. Finally, Sanford C. Bernstein began coverage on shares of Eli Lilly and Company in a research note on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 target price on the stock. Four research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,002.22.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.